Dr. Reddy's plans November 2026 semaglutide relaunch and reiterates 6‑7 million device target
Dr. Reddy's Laboratories said it will relaunch its generic semaglutide in November 2026, with most of the supply destined for Canada and additional volumes for Latin America and Africa. Management reaffirmed its fiscal‑year target of 6 million to 7 million devices and cited an estimated run‑rate of 12 million to 15 million pens for the 12‑month period starting in April. The company reported a 1.5% year‑over‑year revenue decline to INR 8,671 crore and an EBITDA margin of 20.6% for Q2 FY 27, while North America generics revenue fell 29% YoY to $264 million. It also disclosed FDA approval of a rituximab biosimilar and the launch of nivolumab in India.
Why it matters
The semaglutide relaunch could open a new revenue stream in Canada and emerging markets, which the company expects to support its device target (the company expects). The Q2 revenue decline and lower North America generics sales signal short‑term pressure on earnings (the company reported).
Key facts
- 1Semaglutide relaunch is scheduled for November 2026. finance.yahoo.com
- 2Most of the relaunch supply is expected to go to Canada, with additional volumes for Latin America and Africa. finance.yahoo.com
- 3Management reiterated a target of 6 million to 7 million devices for the fiscal year. finance.yahoo.com
- 4North America generics revenue was $264 million, down 29% year over year. finance.yahoo.com
- 5Net cash as of Sept. 30 was INR 2,502 crore. finance.yahoo.com
- 6Full‑year capital expenditures are expected to be INR 1,600 crore to INR 1,700 crore. finance.yahoo.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.